Skip to Content

Insulet posts 24% increase in revenue

Insulet posts 24% increase in revenue

BILLERICA, Mass. - Insulet Corp. has reported fourth quarter revenue of $103.6 million, representing year-over-year growth of 24%. Net loss was $9.2 million vs. $15.9 million. Fourth-quarter revenue in the U.S. for Omnipod was $61.3 million, a 17% increase, and internationally, $20.8 million, a 35% increase. Revenue from drug delivery was $19.6 million, a 34% increase. Insulet reported full year revenue of $367 million, representing year-over-year growth of 39%. Net loss was $27.2 million vs. $61.6 million. Full-year revenue in the U.S. for Omnipod was $229.8 million, a 21% increase, and internationally, $71.9 million, a 78% increase. Revenue from drug delivery was $65.3 million, a 92% increase. Among Insulet's highlights in 2016: its divestiture of Neighborhood Diabetes' medical supplies distribution business to focus on growth opportunities in insulin and drug delivery.

Comments

To comment on this post, please log in to your account or set up an account now.